Signal hyperintensities on brain magnetic resonance imaging in patients with primary Sjögren syndrome and frequent episodic tension-type headache: Relation to platelet serotonin level and disease activity

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1360-1366

  Šarac, Helena ^a   Markeljević, Jasenka ^a   Erdeljić, Viktorija ^b   Josipović Jelić, Zeljka ^c   Hajnšek, Sanja ^a   Klapan, Tatjana ^c   Batinica, Marko ^c   Baršić, Ivana ^b   Sertić, Jadranka ^a   Dintinjana, Renata Dobrila ^d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c Diagnostic Centre Medikol   (Croatia)

^d UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

ESSDAI; Serotonin; Signal hyperintensities; Sjogren syndrome

Indexed keywords

SEROTONIN;

ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE DURATION; EPISODIC TENSION HEADACHE; EUROPEAN LEAGUE AGAINST RHEUMATISM SS DISEASE ACTIVITY INDEX; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SIGNAL DETECTION; SJOEGREN SYNDROME; SPECTROFLUOROMETRY;

ESSDAI; SEROTONIN; SIGNAL HYPERINTENSITIES; SJÖGREN SYNDROME;

ADULT; AGE FACTORS; AGED; BASAL GANGLIA; BLOOD PLATELETS; BRAIN; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREVALENCE; SEROTONIN; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; SPECTROMETRY, FLUORESCENCE; TENSION-TYPE HEADACHE; TIME FACTORS;

EID: 84881468034     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121132     Document Type: Article

References (30)

1. Delalande D, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferrib D, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine 2004;83:280-91.
2. Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvements in Sjogren syndrome. Ann Rheum Dis 2004;63:616-20.
3. Alexander EL, Beall SS, Gordon B, Selnes OA, Yannakakis GD, Patronas N, et al. Magnetic resonance imaging of cerebral lesions in patients with the Sjogren syndrome. Ann Intern Med 1988;108:815-23.
4. Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjogrens syndrome: The role of magnetic resonance imaging. Semin Arthritis Rheum 2004;34:623-30.
5. Bachine S, Duyckaerts C, Hassine L, Chaunu MP, Turell E, Wechsler B, et al. Central and peripheral neurologic lesions in primary Gougerot-Sjogren syndrome. Clinicopathological study of a case. Rev Neurol 1991;147:368-75.
6. Molina R, Provost TT, Alexander EL. Peripheral inflammatory vascular disease in Sjogren's syndrome: Associations with nervous system complications. Arthritis Rheum 1981;24:1495-500.
7. Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, et al. Anti Ro (SSA) autoantibodies in central nervous system disease associated with Sjogren's syndrome: Clinical, neuroimaging, and angiographic correlates. Neurology 1994;44:899-908.
8. Alexander EL. Inflammatory vascular disease in Sjogren's syndrome. In: Talal N, Moutsopoulos HM, Kassan SS. Sjogren's syndrome. Clinical and immunological aspects. Berlin: Springer-Verlag; 1987:102-25.
9. Cikes N, Bosnic D, Sentic M. Non-MS autoimmune demyelination. Clin Neurol Neurosurg 2008;110:905-12.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S, et al. European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia 2004;24 Suppl 1:9-160.
12. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2009;69:1103-9.
13. Jernej B, Banovic M, Cicin-Sain L, Hranilovic D, Balija M, Oreskovic D, et al. Physiological characteristics of platelet/circulatory serotonin: Study on a large human population. Psychiat Res 2000;94:153-62.
14. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
15. Sarac H, Markeljevic J, Mokrovic G, Erdeljic V, Bozina N, Cicin-Sain L. Platelet serotonin in primary Sjogren's syndrome: Level and relation with disease activity. J Neuroimmunol 2012;251:87-9.
16. Escudero D, Latorre P, Codina M, Coll-Canti J, Coll J. Central nervous system disease in Sjogren's syndrome. Ann Med Interne 1995;146:239-42.
17. Coates T, Slavotinek JP, Rischmueller M, Schultz D, Anderson C, Dellamelva M, et al. Cerebral white matter lesions in primary Sjogren's syndrome: A controlled study. J Rheumatol 1999;26:1301-5.
18. Pierot L, Sauve C, Leger JM, Martin N, Koeger AC, Wechsler B, et al. Asymptomatic cerebral involvement in Sjogren syndrome: MRI findings of 15 cases. Neuroradiology 1993;35:378-80.
19. Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, et al. Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkable-Clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology 2010;49:1540-9.
20. Gaultier JC. Atherosclerotic lesions and mechanisms of cerebral ischaemia. Eur Neurol 1978;17 Suppl 1:27-30.
21. Mataro M, Escudero D, Ariza M, Sanchez-Ojanguren J, Latorre P, Junque C, et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjogren syndrome. J Neurol 2003;250:1070-6.
22. Gresele P. The platelet in asthma. In: Page CP, edditor. The platelet in health and disease. Oxford: Blackwell Scientific Publications; 1991:132-57.
23. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010;30:2357-61.
24. Nomura K, Yamano S, Ikeda Y, Yamada H, Fujimoto T, Minami S, et al. Asymptomatic cerebrovascular lesions detected by magnetic resonance imaging in patients with systemic lupus erythematosus lacking a history of neuropsychiatric events. Intern Med 1999;38:785-95.
25. Oxholm P. Primary Sjogren's syndrome-Clinical and laboratory markers of disease activity. Semin Arthritis Rheum 1992;22:114-26.
26. Valtysdotir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol 2001;28:1259-65.
27. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases. Arthritis Rheum 1983;26:532-40.
28. Kostović I, Rakić P. Cytology and time of origin of interstitial neurons in the white matter in infant and adult human and monkey telencephalon. J Neurocytol 1980;9:219-42.
29. Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, et al. The Sjogren's Syndrome Damage Index-A damage index for use in clinical trials and observational studies in primary Sjogren's syndrome. Rheumatology 2008;47:1193-8.
30. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjogren's Syndrome Disease Damage Index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Athritis Rheum 2007;56:2223-31.